{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiezxmanzwp5hcqrjearyv4zhbc2iabbti6blbtx3cvoqip5o37w64",
    "uri": "at://did:plc:mxzzpugn7bprjjrszwkbez3u/app.bsky.feed.post/3mjh5ho2o6kv2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidjnp5dnnekxw6lx5lfnwke42jgr7v3imyxpe45ix6h5been5fsba"
    },
    "mimeType": "image/jpeg",
    "size": 480379
  },
  "path": "/news/2026-04-novo-nordisk-openai-drugs.html",
  "publishedAt": "2026-04-14T04:19:10.000Z",
  "site": "https://techxplore.com",
  "tags": [
    "Machine learning & AI"
  ],
  "textContent": "Danish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a \"strategic partnership\" with OpenAI to accelerate the development of new medications.",
  "title": "Novo Nordisk signs deal with OpenAI to develop new drugs"
}